Loading...
Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)
Non-Hodgkin’s lymphoma (NHL) is the sixth most common cause of cancer deaths in the U.S. Most NHLs initially respond well to chemotherapy, but relapse is common and treatment is often limited due to the toxicity of chemotherapeutic agents. Pegylated-liposomal doxorubicin (PLD, Ben Venue Laboratories...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Springer US
2009
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2850518/ https://ncbi.nlm.nih.gov/pubmed/19306119 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-009-9243-7 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|